| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Sanofi (MX: SNYN)
SNYN Technical Analysis
2
| As on 25th Nov 2025 SNYN STOCK Price closed @ 927.00 and we RECOMMEND Buy for LONG-TERM with Stoploss of 414.30 & Strong Sell for SHORT-TERM with Stoploss of 1030.72 we also expect STOCK to react on Following IMPORTANT LEVELS. |
SNYNSTOCK Price
| Open | 927.00 | Change | Price | % |
| High | 927.00 | 1 Day | -28.00 | -2.93 |
| Low | 927.00 | 1 Week | -17.00 | -1.80 |
| Close | 927.00 | 1 Month | -5.00 | -0.54 |
| Volume | 6 | 1 Year | -48.00 | -4.92 |
| 52 Week High 1212.00 | 52 Week Low 836.00 | ||||
MX Mexico Most Active Stocks
| AMXL | 19.28 | -0.36% |
| PV | 8.50 | 7.32% |
| CEMEXCPO | 19.37 | 2.38% |
| WALMEX | 61.99 | 2.29% |
| FR | 623.87 | 1.01% |
| ALFAA | 14.50 | 1.54% |
| KIMBERA | 38.98 | 5.69% |
| VESTA | 57.06 | 0.53% |
| GMEXICOB | 159.50 | 1.30% |
| GFNORTEO | 174.99 | -0.66% |
MX Mexico Top Gainers Stocks
MX Mexico Top Losers Stocks
| SNYN Daily Charts |
SNYN Intraday Charts |
Whats New @ Bazaartrend |
SNYN Free Analysis |
|
|
SNYN Important Levels Intraday
| RESISTANCE | 927.00 |
| RESISTANCE | 927.00 |
| RESISTANCE | 927.00 |
| RESISTANCE | 927.00 |
| RESISTANCE | 927.00 |
| RESISTANCE | 927.00 |
| RESISTANCE | 927.00 |
| RESISTANCE | 927.00 |
SNYN Forecast November 2025
| 4th UP Forecast | 1223.76 |
| 3rd UP Forecast | 1128.59 |
| 2nd UP Forecast | 1069.76 |
| 1st UP Forecast | 1010.93 |
| 1st DOWN Forecast | 843.07 |
| 2nd DOWN Forecast | 784.24 |
| 3rd DOWN Forecast | 725.41 |
| 4th DOWN Forecast | 630.24 |
SNYN Weekly Forecast
| 4th UP Forecast | 1140.90 |
| 3rd UP Forecast | 1072.30 |
| 2nd UP Forecast | 1029.90 |
| 1st UP Forecast | 987.50 |
| 1st DOWN Forecast | 866.51 |
| 2nd DOWN Forecast | 824.10 |
| 3rd DOWN Forecast | 781.70 |
| 4th DOWN Forecast | 713.10 |
SNYN Forecast2025
| 4th UP Forecast | 1651.55 |
| 3rd UP Forecast | 1419.18 |
| 2nd UP Forecast | 1275.55 |
| 1st UP Forecast | 1131.92 |
| 1st DOWN Forecast | 722.08 |
| 2nd DOWN Forecast | 578.45 |
| 3rd DOWN Forecast | 434.82 |
| 4th DOWN Forecast | 202.45 |
Sanofi ( MX Mexico Symbol : SNYN )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
SNYN Business Profile
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. It also has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration with TrialSpark Inc. to execute clinical research studies in the areas of chronic obstructive pulmonary disease. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France. Address: 54, Rue La BoEtie, Paris, France, 75008
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service